September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
Finerenone Mitigates HF, CV Risk Across Baseline Renal Function in Patients with T2D
The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.
Low-carbohydrate Diet Could Help Improve Untreated HbA1c of 6.0% to 6.9%
In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.
Daily Dose: Oral Superabsorbent Hydrogel Cuts Risk for Type 2 Diabetes
Your daily dose of clinical news you may have missed.
Oral Superabsorbent Hydrogel May Help Prevent Progression of Prediabetes to Type 2 Diabetes: New Research
CMHC 2022. Post-hoc analysis of the LIGHT-UP study found GS200 significantly reduced postprandial insulin secretion in adults with overweight and prediabetes.
PCPs, Cardiologists May Not Adequately Stratify, Treat CV Risk in Patients with Type 2 Diabetes
CMHC. PCPs and cardiologists appeared to perform only half of items considered necessary for care of T2D patients in a new simulated patient study.
Drop in Vitamin D Implies Increased Cardiovascular Risk in T2D, According to New Research
CMHC 2022: A decrease in vitamin D levels is associated with increased cardiovascular risk in patients with type 2 diabetes, according to new study.
Insulin Rationing Common Among Adults with Diabetes, Likely to Avoid High Cost
Analysis of national health data found that 16.5% of all adult insulin users skipped doses in the past year.
Early Diabetes Diagnosis in Women Associated with Early Age at Menopause in Large Canadian Cohort
Early age at either type 1 or type 2 diabetes diagnosis was associated with earlier age a menopause, suggesting an impact of diabetes on reproductive health, authors say.
Cardiometabolic Disease Update: 12 Studies
Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.
Weight Loss is Essential to Optimize Type 2 Diabetes Treatment Management
Weight loss of at least 5% to 10% for persons with T2D is realistic and essential, says Nisa Maruthur, MD, MHS, coauthor of the new ADA/EASD consensus report.
ADA/EASD Consensus Report on T2D Management: Coauthor Talks Take-homes for Primary Care
Nisa Maruthur, MD, MHS, a primary care physician and consensus report coauthor, discusses elements of the most effective care for patients with type 2 diabetes (T2D).
Clinical Practice Guidelines Could be More Primary Care-friendly, says Nisa Maruthur, MD, MHS
Dr Maruthur, a PCP and coauthor for the new ADA/EASD consensus report on T2D, says that's why this report includes the "tips on implementation" sections.
4 New Drugs Approved for Primary Care: Q3 2022
Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.
ADA/EASD Calls for Wide Systemic Change to Address Impact of Social Determinants of Health
As long as the role of social determinants of health in T2D is not prioritized, care for these patients will remain poor and outcomes will not improve, says consensus report author.
SGLT-2 Inhibitors, GLP-1 Receptor Agonists not Cost-effective as First-Line T2D Therapy
When modeled as first-line therapy vs metformin, treatment benefit was significantly outweighed by cost for both classes.
Primary Care Would Benefit from Education on Use of SGLT-2 Inhibitors, GLP-1 Mimetics: Nisa Maruthur, MD, MHS
Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.
Younger Age at Type 2 Diabetes Diagnosis in Adults Increases Risk for Poor Outcomes
A T2D diagnosis in adults aged 50 to 59 years vs 60 to 69 years or ≥70 years was linked to significantly increased risk for cardio- and cerebrovascular disease and all-cause mortality.
ADA, EASD 2022 Consensus Report from the Primary Care Point of View, with Nisa Maruthur, MD, MHS
Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.
Dementia Risk May be Driven by Multimorbidity vs Single Risk Factors, Suggests a New Study
Multimorbidity was associated with a 63% increased risk for dementia among adults older than age 60 years followed for up to 15 years.
ADA, EASD Release Update on Management of Hyperglycemia in Type 2 Diabetes
The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.
T2D Patient Preference Survey Finds Low Side Effect Profile Outranks CVD Protection for Newer OADs
New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.
FreeStyle Libre 3 CGM Linked with Reduced Hospital Admissions in Patients with T2D
Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.
Semaglutide 2.4 mg: Weight Loss in Real-world Study Matches STEP Trial Program Findings
Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.
Tirzepatide Reduces Time to HbA1c Targets by Up to 3 Months vs Semaglutide, Insulin Degludec
Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.
Nocturnal Hypertension: 8 Essential Questions
Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.
Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.
Early-onset Type 2 Diabetes Linked to Significantly Increased Risk for CVD in Later Life: Study
A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.
Specific Blood Pressure Thresholds Not Needed When Selecting Patients with T2D for Antihypertensive Treatment, Suggests New Research
Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.
Diagnoses of Youth-onset Type 2 Diabetes Spiked by 77% During First Year of COVID-19
Youth newly diagnosed with T2D also were metabolically sicker, with higher HbA1c, serum glucose levels, and BMI at presentation.
New Novo Nordisk Combination Rx Better than Components for T2D, Weight Loss
Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.